Novadaq Technologies Inc.TSX: NDQ

Novadaq Announces European Distribution Contract with Kodak

· Issued by Novadaq Technologies Inc. via CNW
New Contract Adds to Kodak's Role as U.S. Service Provider for Novadaq's
SPY System

TORONTO, Sept. 8 /CNW/ - Novadaq(R) Technologies Inc. (TSX: NDQ), a
developer of medical imaging systems for the operating room, today announced
it has signed an agreement with Eastman Kodak Company, authorizing Kodak to be
the sole European and Emerging Markets distributor of Novadaq's SPY(R)
Intra-operative Imaging System which is used during cardiac surgery. Under the
agreement, Kodak will sell Novadaq's SPY System directly and through dealers
to healthcare providers across Europe and Emerging Markets.
"Cardiac surgeons have seen the significant benefits the SPY System
provides during cardiac surgery, including coronary artery bypass graft
surgery which is one of the most challenging surgeries performed," said Dr.
Arun Menawat, President and Chief Executive Officer of Novadaq Technologies
Inc. "With Kodak's worldwide presence in the medical imaging market, we expect
to see a successful rollout of the SPY System in Europe and Emerging Markets
just as we have in the U.S."
"Kodak has strong relationships with physicians and hospitals throughout
the world and an experienced and knowledgeable sales force that healthcare
providers trust," said Gordon Moore, Product Line Manager, MVES Surgical
Imaging. "Together our companies will strive to accelerate the acceptance of
the SPY System to make it the standard of care during cardiac surgery."
Novadaq's SPY System is a fluorescent imaging system that enables cardiac
surgeons to assess coronary vasculature, and to identify and revise anatomic
and technical deficiencies while the patient is still in the operating room.
In 2005, Novadaq selected Kodak as the sole U.S. service provider for the
SPY System, based on its expertise in medical imaging and geographic coverage
offered by its extensive Services organization. Kodak currently is servicing
an install base of SPY Systems in over 50 leading healthcare facilities in the
U.S.

About Kodak's Health Group
Kodak's Health Group, with 2005 revenues of $2.65 billion, is a world
leader in supplying the medical and dental professions with advanced
healthcare products, services and information technology solutions. Its broad
portfolio includes picture archiving and communications systems (PACS),
radiology information systems (RIS), healthcare information systems, computed
radiography (CR) and digital radiography (DR) systems, laser imagers,
mammography and oncology systems, x-ray film systems, dental imaging products,
and a range of consulting - as well as repair and maintenance - services.
Kodak is the world's foremost imaging innovator, providing leading
products and services to not only healthcare customers, but to the
photographic and graphic communications markets. With sales of $14.3 billion
in 2005, the company is committed to a digitally oriented growth strategy
focused on helping people better use meaningful images and information in
their life and work. Consumers use Kodak's system of digital and traditional
image capture products and services to take, print and share their pictures
anytime, anywhere; Businesses effectively communicate with customers worldwide
using Kodak solutions for prepress, conventional and digital printing and
document imaging; and Creative Professionals rely on Kodak technology to
uniquely tell their story through moving or still images.
For more information about Kodak's Health Group, contact your Kodak
representative or visit www.kodak.com/go/health.

DAK is a trademark of Eastman Kodak Company.
(C) Eastman Kodak Company, 2006

About Novadaq Technologies
Novadaq Technologies Inc. (TSX: NDQ) develops and commercializes medical
devices based on its proprietary imaging platform for the diagnosis and
treatment of human vascular and ophthalmic diseases and conditions. Novadaq's
SPY Intra-operative Imaging System, commercially available worldwide, enables
cardiac surgeons to visually assess coronary vasculature and bypass graft
functionality during the course of open-heart surgery. Novadaq's ophthalmic
product, the OPTTX(R) System, is aimed at the diagnosis, evaluation and
treatment of wet Age-related Macular Degeneration (AMD) by using the same core
imaging technology that is used in the SPY System. Novadaq filed for CE Mark
for the OPTTX System at the end of Q2 2006 and expects a limited launch in
Europe by year end. Novadaq's product for urology, LUNA(TM) is designed to
enable surgeons to visualize nerve bundles during the course of urological
procedures such as radical prostatectomy in order to reduce negative outcomes
including impotency. For more information, please visit the company's website
at www.novadaq.com.

This press release contains certain information that may constitute
forward-looking information within the meaning of securities laws. In some
cases, forward-looking information can be identified by the use of terms such
as "may", "will", "should", "expect", "plan", "anticipate", "believe",
"intend", "estimate", "predict", "potential", "continue" or other similar
expressions concerning matters that are not historical facts. Forward-looking
information may relate to management's future outlook and anticipated events
or results, and may include statements or information regarding the future
financial position, business strategy and strategic goals, research and
development activities, projected costs and capital expenditures, financial
results, research and clinical testing outcomes, and plans and objectives of
or involving Novadaq. Particularly, information regarding future sales and
marketing activities, the future roll-out of the SPY System in Europe and
Emerging Markets, future revenues and research and development activities,
expectations for regulatory approval and commercial launch of the OPTTX
System, as well as the Company's plans for each of the SPY, OPTTX and Luna
Systems, is forward-looking information.
Forward-looking information is based on certain factors and assumptions
regarding, among other things, current sales and distribution plans, market
acceptance and the rate of market penetration of Novadaq's SPY System, the
clinical results of the use of the SPY System, the results from clinical tests
of the OPTTX System, the likelihood of regulatory approval in Europe for the
OPTTX System, potential opportunities in the AMD treatment market, and
potential opportunities in image guided conventional and minimally invasive
urological applications including nerve-sparing radical prostatectomy. While
the Company considers these assumptions to be reasonable based on information
currently available to it, they may prove to be incorrect.
Forward looking-information is subject to certain factors, including
risks and uncertainties that could cause actual results to differ materially
from what we currently expect. These factors include risks relating to the
transition from research and development activities to commercial activities,
market acceptance and adoption of the SPY System, sales and distribution
risks, dependence on key suppliers for components of the SPY System and the
OPTTX System, regulatory and clinical risks, risks relating to the protection
of intellectual property, risks inherent in the conduct of research and
development activities, including the risk of unfavorable or inconclusive
clinical trial outcomes, potential product liability, competition and the
risks posed by potential technological advances, and risks relating to
fluctuations in the exchange rate between the US dollar and the Canadian
dollar.
You should not place undue importance on forward-looking information and
should not rely upon this information as of any other date. While Novadaq may
elect to, Novadaq is under no obligation and does not undertake to update this
information at any particular time.

%SEDAR: 00022069E

Novadaq Technologies Inc. on 6ix

Story so far

Earlier from Novadaq Technologies

Later from Novadaq Technologies

All Novadaq Technologies news releases